Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
US12247984B2 · kind B2 · utility
0Cited by
4References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 18, 2020 |
| Grant date | Mar 11, 2025 |
| Priority date | — |
| Expiry date | Sep 3, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/43582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.